🟢 Moderna is trading 4.72% up today after Phase 3 trial met recurrence-free-survival endpoint

Moderna is trading 4.72% up at $190.70 after positive Phase 3 INTerpath-001 results for intismeran autogene with Merck’s Keytruda.

• The trial met its recurrence-free-survival primary endpoint and distant-metastasis-free-survival secondary endpoint, supporting continued investor enthusiasm for Moderna’s personalized cancer-vaccine program.
• The move extends gains following the September 23 announcement, despite biotechnology stocks and broader markets trading lower.